ES2176755T3 - Derivados anticonvulsivos utiles para el tratamiento de la esclerosis lateral amiotrofica. - Google Patents

Derivados anticonvulsivos utiles para el tratamiento de la esclerosis lateral amiotrofica.

Info

Publication number
ES2176755T3
ES2176755T3 ES97931367T ES97931367T ES2176755T3 ES 2176755 T3 ES2176755 T3 ES 2176755T3 ES 97931367 T ES97931367 T ES 97931367T ES 97931367 T ES97931367 T ES 97931367T ES 2176755 T3 ES2176755 T3 ES 2176755T3
Authority
ES
Spain
Prior art keywords
convulsive
derivatives
treatment
lateral sclerosis
useful anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97931367T
Other languages
English (en)
Inventor
Richard P Shank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of ES2176755T3 publication Critical patent/ES2176755T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNOS DERIVADOS ANTICONVULSIVOS QUE SIRVEN PARA EL TRATAMIENTO DE LA ESCLEROSIS LATERAL AMIOTROFICA.
ES97931367T 1996-06-28 1997-06-24 Derivados anticonvulsivos utiles para el tratamiento de la esclerosis lateral amiotrofica. Expired - Lifetime ES2176755T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2200696P 1996-06-28 1996-06-28

Publications (1)

Publication Number Publication Date
ES2176755T3 true ES2176755T3 (es) 2002-12-01

Family

ID=21807346

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97931367T Expired - Lifetime ES2176755T3 (es) 1996-06-28 1997-06-24 Derivados anticonvulsivos utiles para el tratamiento de la esclerosis lateral amiotrofica.

Country Status (22)

Country Link
US (1) US5753694A (es)
EP (1) EP0936908B1 (es)
JP (1) JP2000514426A (es)
AP (1) AP1167A (es)
AT (1) ATE214274T1 (es)
AU (1) AU725093B2 (es)
BR (1) BR9710993A (es)
CA (1) CA2258892C (es)
CZ (1) CZ293945B6 (es)
DE (1) DE69711067T2 (es)
DK (1) DK0936908T3 (es)
ES (1) ES2176755T3 (es)
HU (1) HUP9904318A3 (es)
IL (1) IL127717A (es)
NO (1) NO317136B1 (es)
NZ (1) NZ333588A (es)
PT (1) PT936908E (es)
SI (1) SI0936908T1 (es)
SK (1) SK284331B6 (es)
UA (1) UA46112C2 (es)
WO (1) WO1998000131A1 (es)
ZA (1) ZA975764B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
US6583172B1 (en) 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
ES2542892T3 (es) 1999-06-14 2015-08-12 Vivus, Inc. Terapia de combinación para el tratamiento de hipertensión asociada con la obesidad
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
WO2002043731A2 (en) * 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
ATE361089T1 (de) 2001-02-02 2007-05-15 Ortho Mcneil Pharm Inc Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
JP2005514352A (ja) * 2001-11-14 2005-05-19 ラルフ ライバック 自己免疫疾患の治療法
US20060041022A1 (en) * 2002-11-06 2006-02-23 Pasinetti Giulio M Treatment of amyotrophic lateral sclerosis with nimesulide
CA2505514A1 (en) * 2002-11-06 2004-05-27 Mount Sinai School Of Medicine Treatment of amyotrophic lateral sclerosis with nimesulide
WO2005000294A1 (en) * 2003-06-06 2005-01-06 Pharmacia Corporation Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
AU2005277134A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
IS7748A (is) * 2005-03-17 2006-09-18 Actavis Group Samsetning fyrir töflur sem innihalda topiramate
EA200702558A1 (ru) * 2005-05-20 2008-06-30 Янссен Фармацевтика Н. В. Способ получения производных сульфамида
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
FR2903019A1 (fr) * 2006-06-30 2008-01-04 Univ Claude Bernard Lyon I Eta Utilisation d'un inhibiteur de l'anhydrase carbonique, pour la preparation d'un medicament destine a traiter des degenerescences du muscle squelettique
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates

Also Published As

Publication number Publication date
CZ427998A3 (cs) 1999-08-11
ZA975764B (en) 1998-12-28
CA2258892C (en) 2005-08-09
EP0936908A1 (en) 1999-08-25
HUP9904318A3 (en) 2001-02-28
SK284331B6 (sk) 2005-01-03
IL127717A (en) 2004-09-27
DE69711067T2 (de) 2002-09-19
AP9801428A0 (en) 1998-12-31
CZ293945B6 (cs) 2004-08-18
NO317136B1 (no) 2004-08-23
HUP9904318A2 (hu) 2000-05-28
BR9710993A (pt) 2002-02-26
AU725093B2 (en) 2000-10-05
SK180698A3 (en) 2000-07-11
AU3501097A (en) 1998-01-21
DK0936908T3 (da) 2002-05-27
CA2258892A1 (en) 1998-01-08
DE69711067D1 (de) 2002-04-18
ATE214274T1 (de) 2002-03-15
EP0936908B1 (en) 2002-03-13
US5753694A (en) 1998-05-19
JP2000514426A (ja) 2000-10-31
SI0936908T1 (en) 2002-12-31
WO1998000131A1 (en) 1998-01-08
NO986054D0 (no) 1998-12-22
PT936908E (pt) 2002-08-30
UA46112C2 (uk) 2002-05-15
NZ333588A (en) 2000-07-28
IL127717A0 (en) 1999-10-28
AP1167A (en) 2003-06-30
NO986054L (no) 1999-03-01

Similar Documents

Publication Publication Date Title
ES2176755T3 (es) Derivados anticonvulsivos utiles para el tratamiento de la esclerosis lateral amiotrofica.
HN1997000126A (es) Derivados de indazol
HN1997000166A (es) 1-arilpirazoles plaguicidas
HN1996000101A (es) Terapia combinada para la osteoporosis
HN1997000023A (es) Derivados de lactama
HN1998000132A (es) Combinaciones terapeuticas
HN1997000099A (es) Inhibidores de metaloproteasas matriciales basados en
HN1997000146A (es) Derivados de pirimidina biciclica condensada
ES2180899T3 (es) Dihidrato d de olanzapina.
HN1999000096A (es) Formulaciones intranasales para tratar trastornos sexuales
HN1997000058A (es) Derivados indolicos utiles para terapia
HN1998000118A (es) 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
HN1998000020A (es) Derivados de acido arilsulfonilhidroxamico.
HN1998000174A (es) Combinacion eficaz para el tratamiento de la impotencia
HN1997000144A (es) Amidas inhibidoras de la secrecion de apo blmtp
HN1998000160A (es) Sistema constructivo modular hondulog
HN1998000158A (es) Isoquinolinas
HN1998000185A (es) Combinaciones de estadina-eter carboxialquilico
SE9801494D0 (sv) Novel use
HN1998000199A (es) Agentes terapeuticos
HN1997000127A (es) Procedimiento e intermedios para preparar derivados de cromanol sustituidos.
ES2154692T3 (es) Dihidrofarnesal.
HN1998000165A (es) Polimorfos dofetilina
HN1999000038A (es) Nuevos compuestos fungicidas
ES2136443T3 (es) Limpieza in situ.